Linklaters has secured various unconditional merger control and foreign investment clearances for Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, in relation to its investment in Biocomposites, an international medical devices company that engineers, manufactures and markets leading products for use in infection management in bone and soft tissue.
As part of the transaction TA Associates, Biocomposites’ majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites’ management. The transaction gives Novo Holdings and TA Associates shared control of Biocomposites.
Since partnering with TA Associates in 2017, Biocomposites has achieved significant growth – including a threefold increase in revenues, successful geographic expansion, and continued product diversification. The Company has also completed two strategic acquisitions, strengthening its international presence and enabling entry into adjacent indications and therapeutic areas. With the new investment from Novo Holdings and the ongoing support of TA Associates, Biocomposites aims to build on this momentum, deepening its global footprint and further advancing its pipeline of innovative products to deliver life-changing solutions at scale.
Linklaters advised on the multijurisdictional merger control and foreign investment aspects of the transaction, securing unconditional clearances in first phase reviews across the globe. The filing jurisdictions included the EU, Switzerland and Turkey.
The team was led by Partner and Head of U.S. Antitrust & Foreign Investment Group Antonia Sherman. The core team also included Antitrust & Foreign Investment Counsel Mark Daniel, Managing Associate Juliane Guderian, and Associates Marilena Nteve and Anna Veispak.
